Links for fulltext
     (May Require Subscription)
Supplementary

Article: Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients

TitleFludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients
Authors
Issue Date2004
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJH
Citation
British Journal Of Haematology, 2004, v. 124 n. 6, p. 754-761 How to Cite?
AbstractThe treatment results of indolent lymphoid malignancies in Chinese are poorly reported. The efficacy of FND (fludarabine 25 mg/m2/d, x3; mitoxantrone 10 mg/m2/d, x1; dexamethasone 20 mg/d, x5; monthly cycles, x6) in 95 Chinese patients with indolent B-cell malignancies (at diagnosis: 55, relapse/refractory disease: 40) and nine Chinese patients with T-cell large granular lymphocyte leukaemia (T-LGL leukaemia) (at diagnosis: two, refractory disease: seven) was evaluated. For B-cell malignancies, the complete response (CR), partial response (PR) and overall response (OR) rates were 50.5%, 18% and 68.5% respectively. Better results were obtained for primary versus relapse/refractory disease (CR: 60% vs. 37-5%, P = 0.03; OR: 84% vs. 47.5%, P < 0.001; median progression-free survival (PFS): 44 months vs. 22 months; 2-year PFS: 66% vs. 47%, P = 0.039; overall survival (OS): not reached vs. 32%; 2-year OS: 92% vs. 58%, P < 0.001). Responsive patients (CR/PR) had a better median PFS (44 months vs. 5 months, P < 0.001) and OS (67 months vs. 13 months, P < 0.001) than unresponsive patients. For T-LGL leukaemia, the CR and molecular-remission rates were 56% and 67% (median follow-up: 23 months). FND is an active regimen for the treatment of indolent B- and T-cell malignancies in Chinese patients, with results comparable with Western patients with similar indolent lymphomas. © 2004 Blackwell Publishing Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/162809
ISSN
2015 Impact Factor: 5.401
2015 SCImago Journal Rankings: 2.313
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorMa, SYen_US
dc.contributor.authorAu, WYen_US
dc.contributor.authorChim, CSen_US
dc.contributor.authorLie, AKWen_US
dc.contributor.authorLam, CCKen_US
dc.contributor.authorTse, Een_US
dc.contributor.authorLeung, AYHen_US
dc.contributor.authorLiang, Ren_US
dc.contributor.authorKwong, YLen_US
dc.date.accessioned2012-09-05T05:23:48Z-
dc.date.available2012-09-05T05:23:48Z-
dc.date.issued2004en_US
dc.identifier.citationBritish Journal Of Haematology, 2004, v. 124 n. 6, p. 754-761en_US
dc.identifier.issn0007-1048en_US
dc.identifier.urihttp://hdl.handle.net/10722/162809-
dc.description.abstractThe treatment results of indolent lymphoid malignancies in Chinese are poorly reported. The efficacy of FND (fludarabine 25 mg/m2/d, x3; mitoxantrone 10 mg/m2/d, x1; dexamethasone 20 mg/d, x5; monthly cycles, x6) in 95 Chinese patients with indolent B-cell malignancies (at diagnosis: 55, relapse/refractory disease: 40) and nine Chinese patients with T-cell large granular lymphocyte leukaemia (T-LGL leukaemia) (at diagnosis: two, refractory disease: seven) was evaluated. For B-cell malignancies, the complete response (CR), partial response (PR) and overall response (OR) rates were 50.5%, 18% and 68.5% respectively. Better results were obtained for primary versus relapse/refractory disease (CR: 60% vs. 37-5%, P = 0.03; OR: 84% vs. 47.5%, P < 0.001; median progression-free survival (PFS): 44 months vs. 22 months; 2-year PFS: 66% vs. 47%, P = 0.039; overall survival (OS): not reached vs. 32%; 2-year OS: 92% vs. 58%, P < 0.001). Responsive patients (CR/PR) had a better median PFS (44 months vs. 5 months, P < 0.001) and OS (67 months vs. 13 months, P < 0.001) than unresponsive patients. For T-LGL leukaemia, the CR and molecular-remission rates were 56% and 67% (median follow-up: 23 months). FND is an active regimen for the treatment of indolent B- and T-cell malignancies in Chinese patients, with results comparable with Western patients with similar indolent lymphomas. © 2004 Blackwell Publishing Ltd.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJHen_US
dc.relation.ispartofBritish Journal of Haematologyen_US
dc.rightsBritish Journal of Haematology. Copyright © Blackwell Publishing Ltd.-
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshAntibodies, Monoclonal - Administration & Dosageen_US
dc.subject.meshAntibodies, Monoclonal, Murine-Deriveden_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Administration & Dosage - Adverse Effects - Therapeutic Useen_US
dc.subject.meshAsian Continental Ancestry Groupen_US
dc.subject.meshDexamethasone - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshDisease-Free Survivalen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLeukemia, Prolymphocytic, T-Cell - Drug Therapy - Ethnologyen_US
dc.subject.meshLymphoma, B-Cell - Drug Therapy - Ethnologyen_US
dc.subject.meshLymphoma, Non-Hodgkin - Drug Therapy - Ethnologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshMitoxantrone - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshSurvival Analysisen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshVidarabine - Administration & Dosage - Adverse Effects - Analogs & Derivativesen_US
dc.titleFludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patientsen_US
dc.typeArticleen_US
dc.identifier.emailChim, CS:jcschim@hku.hken_US
dc.identifier.emailTse, E:ewctse@hku.hken_US
dc.identifier.emailLeung, AYH:ayhleung@hku.hken_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.authorityChim, CS=rp00408en_US
dc.identifier.authorityTse, E=rp00471en_US
dc.identifier.authorityLeung, AYH=rp00265en_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1111/j.1365-2141.2004.04852.xen_US
dc.identifier.pmid15009063-
dc.identifier.scopuseid_2-s2.0-1642346015en_US
dc.identifier.hkuros87679-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-1642346015&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume124en_US
dc.identifier.issue6en_US
dc.identifier.spage754en_US
dc.identifier.epage761en_US
dc.identifier.isiWOS:000189294500007-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridMa, SY=7403725725en_US
dc.identifier.scopusauthoridAu, WY=7202383089en_US
dc.identifier.scopusauthoridChim, CS=7004597253en_US
dc.identifier.scopusauthoridLie, AKW=24284842400en_US
dc.identifier.scopusauthoridLam, CCK=16947291300en_US
dc.identifier.scopusauthoridTse, E=7005019454en_US
dc.identifier.scopusauthoridLeung, AYH=7403012668en_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats